604 Results for "

SCO2 mutations

" in MedChemExpress (MCE) Product Catalog:
Products (604)

604 Results for "SCO2 mutations" in MCE Product Catalog:

Cat. No.: HY-P3846
CAS No.: 1802086-22-1
Target:  

Amyloid-β

Research Areas:  

Neurological Disease

(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease [2].
loading...
    loading...
Cat. No.: HY-W720550
CAS No.: 3012-64-4
Synonyms: 5,6-Epoxy-RP
Research Areas:  

Cancer

5,6-Epoxyretinyl palmitate (5,6-Epoxy-RP) is one of the main photodegradation products of Retinyl palmitate (HY-B1384) produced under UVA light irradiation. 5,6-Epoxyretinyl palmitate exhibits phototoxicity to cells and causes significant DNA single-strand breaks, DNA damage, and chromosomal mutations under light conditions .
loading...
    loading...
Cat. No.: HY-109189A
CAS No.: 2170255-78-2
Synonyms: BPI-7711 hydrochloride
Target:  

EGFR

Research Areas:  

Cancer

Rezivertinib (BPI-7711) hydrochloride is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib hydrochloride exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib hydrochloride has excellent central nervous system (CNS) penetration and has antitumor activity, such as non-small cell lung cancer (NSCLC) [2].
loading...
    loading...
Cat. No.: HY-114491
CAS No.: 1715025-32-3
Purity:  99.83%
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF [2].
loading...
    loading...
Cat. No.: HY-114491A
CAS No.: 1715025-34-5
Purity:  99.81%
Target:  

ERK Raf

Research Areas:  

Cancer

Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF [2].
loading...
    loading...
Cat. No.: HY-123803
CAS No.: 2213468-04-1
Target:  

Potassium Channel

Research Areas:  

Cardiovascular Disease

PF-06807656 is a selective renal outer medullary potassium channel (ROMK or Kir1.1) inhibitor. PF-06807656 has an IC50 of 61 nM against hROMK in patch-clamp assays. PF-06807656 exhibits high selectivity for inhibiting rat ROMK and is insensitive to N171D pore mutations. PF-06807656 may be used in cardiovascular disease research .
loading...
    loading...
Cat. No.: HY-125494A
CAS No.: 159910-86-8
Synonyms: SC-55389A free base
Target:  

HIV HIV Protease

Research Areas:  

Infection

Droxinavir (SC-55389A free base) is an HIV-1 protease inhibitor. Droxinavir binds to the S2 and S2' subsites of HIV-1 protease, and this interaction is regulated by protease amino acid residue 88, where the N88S mutation confers viral resistance. Droxinavir can be used in studies related to human immunodeficiency virus type 1 infection .
loading...
    loading...
Cat. No.: HY-138302
CAS No.: 2067281-52-9
Target:  

Drug Intermediate

Research Areas:  

Cancer

PF-06862309 is a PF-06843195 (HY-131972) phosphate ester prodrug. PF-06862309 can be hydrolyzed to PF-06843195 in the presence of alkaline phosphatase. PF-06843195 is a highly selective PI3Kα inhibitor. PF-06862309 can be used for the study of breast cancer with ER +, HER 2-, and PIK3CA mutations .
loading...
    loading...
Cat. No.: HY-138697
CAS No.: 1644600-79-2
Purity:  99.91%
Synonyms: VOB560
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

S65487 (VOB560), a potent and selective BCL-2 inhibitor, is a proagent of S55746. S65487 is also active on BCL-2 mutations, such as G101V and D103Y. S65487 has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 induces apoptosis and has anticaner activities [2].
loading...
    loading...
Cat. No.: HY-138697B
CAS No.: 1644543-95-2
Purity:  99.67%
Synonyms: VOB560 hydrochloride
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

S65487 (VOB560) hydrochloride, a potent and selective Bcl-2 inhibitor, is a proagent of S55746. S65487 hydrochloride is also active on BCL-2 mutations, such as G101V and D103Y. S65487 hydrochloride has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 hydrochloride induces apoptosis and has anticaner activities [2].
loading...
    loading...
Cat. No.: HY-148792
CAS No.: 2392951-29-8
Purity:  99.13%
Synonyms: PRAX-562
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Relutrigine (PRAX-562) is an orally active inhibitor of persistent sodium channel. Relutrigine potently and preferentially inhibits persistent INa induced by ATX-II (Nav 1.5 activator) or the SCN8A mutation N1768D with IC50 values of 141 nM and 75 nM, respectively. Relutrigine exhibits potent use-dependent block and reduces neuronal intrinsic excitability. Relutrigine has effective anticonvulsant activity .
loading...
    loading...
Cat. No.: HY-153399
CAS No.: 2415715-84-1
Synonyms: ABBV-CLS-7262
Fosigotifator (ABBV-CLS-7262) is a brain penetrant, orally active EIF2b (eukaryotic initiation factor) activator. Fosigotifator stabilizes the elF2B complex and boosts the activity, including that of complexes carrying pathogenic vanishing white matter (VWM) mutations. Fosigotifator is an integrated stress response inhibitor (ISRI). Fosigotifator can be used for amyotrophic lateral sclerosis research [2].
loading...
    loading...
Cat. No.: HY-168013
Target:  

Ras

Research Areas:  

Cancer

KRASG12C IN-14 (compound 15) is an inhibitor targeting the KRAS G12C mutation. KRASG12C IN-14 inhibits CYPA-dependent KRAS-BRAF with an IC50 of 0.002 μM. KRASG12C IN-14 inhibits ERK phosphorylation in NCI-H358 cells with an IC50 of 0.002 μM .
loading...
    loading...
Cat. No.: HY-169228
CAS No.: 2759280-09-4
Target:  

Btk

Research Areas:  

Cancer

WS-11 is a non-covalent reversible BTK inhibitor with IC50s of 3.9 nM and 2.2 nM for wild type, C481S mutation BTK, respectively. WS-11 can form strong π-π interaction with PHE540 and form p-π interaction with LYS430 within the active pocket, besides the strong hydrogen bonds .
loading...
    loading...
Cat. No.: HY-N1996R
CAS No.: 23094-71-5
Chebulagic acid (Standard) is the analytical standard of Chebulagic acid. This product is intended for research and analytical applications. Chebulagic acid is a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a M2 serine to asparagine 31 mutation (S31N) inhibitor and influenza antiviral. Chebulagic acid also against SARS-CoV-2 viral replication with an EC50 of 9.76 μM.
loading...
    loading...
Cat. No.: HY-P10999
Synonyms: P55
Research Areas:  

Others

INF7TAT-P55 (P55) is a polypeptide derived from INF7TAT (HY-P11000) with G1K, G20L and Y22N mutations. INF7TAT-P55 serves as a delivery carrier to deliver preassembled CRISPR ribonucleases into cells for genome editing .
loading...
    loading...
Cat. No.: HY-P10999A
Synonyms: P55 acetate
Research Areas:  

Others

INF7TAT-P55 acetate (P55 acetate) is a polypeptide derived from INF7TAT (HY-P11000) with G1K, G20L and Y22N mutations. INF7TAT-P55 acetate serves as a delivery carrier to deliver preassembled CRISPR ribonucleases into cells for genome editing .
loading...
    loading...
Cat. No.: HY-P11089
CAS No.: 151808-74-1
Target:  

MHC

Research Areas:  

Cancer

TP53 neoepitope is a high-affinity antigenic peptide targeting HLA-A. TP53 neoepitope can triggers CD8 + T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .
loading...
    loading...
Cat. No.: HY-P1383A
Target:  

Ras

Research Areas:  

Others

Rac1 Inhibitor F56, control peptide TFA is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor F56, control peptide TFA contains a Trp 56 to Phe 56 mutation. Rac1 Inhibitor F56, control peptide TFA has no effect on Rac1 interaction with its guanine nucleotide exchange factors (GEFs) .
loading...
    loading...
Cat. No.: HY-W013053
CAS No.: 53-70-3
Synonyms: DBA; 1,2,5,6-Dibenzanthracene; Benzo[k]tetraphene
Dibenz[a,h]anthracene (DBA) is an orally active polycyclic aromatic hydrocarbon, a by-product of incomplete combustion of organic matter, a potent carcinogen, and an agonist of AhR. Dibenz[a,h]anthracene induces dose-dependent increases in DNA adduct formation and lacZ mutation frequency. Dibenz[a,h]anthracene upregulates St3gal5. Dibenz[a,h]anthracene can be used in cancer-related research .
loading...
    loading...